// App-Quantinova.ai

M2178 2016 AHA : Empagliflozin Reduces Markers of Arterial Stiffness, Vascular Resistance and Cardiac Workload in EMPA-REG OUTCOME

Researchers

Presenter

  • Lars Gullestad

Principal Investigators

  • David Fitchett

  • Silvio E Inzucchi

  • Michaela Mattheus

  • Hans Juergen Woerle

  • Odd Erik Johansen

Medical Centers

  • Yale Univ Schl of Med, New Haven, CT

  • Oslo Univ Hosp, Rikshospitalet, Oslo, Norway

  • St. Michael's Hosp, Toronto, ON, Canada

  • Univ of Texas Hlth Sci Ctr, San Antonio, TX

Locations

  • United States

  • Canada

  • Norway

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Myocardial infarction

  • Arterial stiffness

  • Type 2 diabetes mellitus

  • Diabetes

  • Stroke

Biomarkers

  • GC Vitamin D Binding Protein

  • Sex hormone binding globulin

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved